225 related articles for article (PubMed ID: 26365799)
1. Structural Basis of Telomerase Inhibition by the Highly Specific BIBR1532.
Bryan C; Rice C; Hoffman H; Harkisheimer M; Sweeney M; Skordalakes E
Structure; 2015 Oct; 23(10):1934-1942. PubMed ID: 26365799
[TBL] [Abstract][Full Text] [Related]
2. Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes.
Hoffman H; Rice C; Skordalakes E
J Biol Chem; 2017 Mar; 292(11):4593-4601. PubMed ID: 28154186
[TBL] [Abstract][Full Text] [Related]
3. A motif in the vertebrate telomerase N-terminal linker of TERT contributes to RNA binding and telomerase activity and processivity.
Harkisheimer M; Mason M; Shuvaeva E; Skordalakes E
Structure; 2013 Oct; 21(10):1870-8. PubMed ID: 24055314
[TBL] [Abstract][Full Text] [Related]
4. A critical stem-loop structure in the CR4-CR5 domain of mammalian telomerase RNA.
Chen JL; Opperman KK; Greider CW
Nucleic Acids Res; 2002 Jan; 30(2):592-7. PubMed ID: 11788723
[TBL] [Abstract][Full Text] [Related]
5. RNA-protein binding interface in the telomerase ribonucleoprotein.
Bley CJ; Qi X; Rand DP; Borges CR; Nelson RW; Chen JJ
Proc Natl Acad Sci U S A; 2011 Dec; 108(51):20333-8. PubMed ID: 22123986
[TBL] [Abstract][Full Text] [Related]
6. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
7. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
8. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
[TBL] [Abstract][Full Text] [Related]
10. Analysis of a long-range interaction between conserved domains of human telomerase RNA.
Ueda CT; Roberts RW
RNA; 2004 Jan; 10(1):139-47. PubMed ID: 14681592
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate.
Pascolo E; Wenz C; Lingner J; Hauel N; Priepke H; Kauffmann I; Garin-Chesa P; Rettig WJ; Damm K; Schnapp A
J Biol Chem; 2002 May; 277(18):15566-72. PubMed ID: 11854300
[TBL] [Abstract][Full Text] [Related]
12. Structure of the Tribolium castaneum telomerase catalytic subunit TERT.
Gillis AJ; Schuller AP; Skordalakes E
Nature; 2008 Oct; 455(7213):633-7. PubMed ID: 18758444
[TBL] [Abstract][Full Text] [Related]
13. A Non-Toxic Concentration of Telomerase Inhibitor BIBR1532 Fails to Reduce
Pandya VA; Crerar H; Mitchell JS; Patani R
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33806803
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Preparation and Crystallization of Vertebrate Telomerase Subunits.
Huang J; Bley CJ; Rand DP; Chen JJ; Lei M
Methods Mol Biol; 2017; 1587():161-169. PubMed ID: 28324508
[TBL] [Abstract][Full Text] [Related]
15. Human telomerase RNA-protein interactions.
Bachand F; Triki I; Autexier C
Nucleic Acids Res; 2001 Aug; 29(16):3385-93. PubMed ID: 11504876
[TBL] [Abstract][Full Text] [Related]
16. Structure and function of the N-terminal domain of the yeast telomerase reverse transcriptase.
Petrova OA; Mantsyzov AB; Rodina EV; Efimov SV; Hackenberg C; Hakanpää J; Klochkov VV; Lebedev AA; Chugunova AA; Malyavko AN; Zatsepin TS; Mishin AV; Zvereva MI; Lamzin VS; Dontsova OA; Polshakov VI
Nucleic Acids Res; 2018 Feb; 46(3):1525-1540. PubMed ID: 29294091
[TBL] [Abstract][Full Text] [Related]
17. Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions.
Bachand F; Autexier C
Mol Cell Biol; 2001 Mar; 21(5):1888-97. PubMed ID: 11238925
[TBL] [Abstract][Full Text] [Related]
18. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies.
Biray Avci C; Dogan F; Ozates Ay NP; Goker Bagca B; Abbaszadeh Z; Gunduz C
J Cell Biochem; 2018 Dec; 119(12):9817-9824. PubMed ID: 30145821
[TBL] [Abstract][Full Text] [Related]
19. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
20. Folding heterogeneity in the essential human telomerase RNA three-way junction.
Palka C; Forino NM; Hentschel J; Das R; Stone MD
RNA; 2020 Dec; 26(12):1787-1800. PubMed ID: 32817241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
